<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36711478</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.01.18.23284742</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.01.18.23284742</ELocationID><Abstract><AbstractText>The incidence of long COVID is substantial, even in people who did not require hospitalization for acute COVID-19. The pathobiological mechanisms of long COVID and the role of early viral kinetics in its development are largely unknown. Seventy-three non-hospitalized adult participants were enrolled within approximately 48 hours of their first positive SARS-CoV-2 RT-PCR test, and mid-turbinate nasal and saliva samples were collected up to 9 times within the first 45 days after enrollment. Samples were assayed for SARS-CoV-2 using RT-PCR and additional test results were abstracted from the clinical record. Each participant indicated the presence and severity of 49 long- COVID symptoms at 1-, 3-, 6-, 12-, and 18-months post-COVID-19 diagnosis. Time from acute COVID-19 illness onset to SARS-CoV-2 RNA clearance greater or less than 28 days was tested for association with the presence or absence of each of 49 long COVID symptoms at 90+ days from acute COVID-19 symptom onset. Brain fog and muscle pain at 90+ days after acute COVID-19 onset were negatively associated with viral RNA clearance within 28 days of acute COVID-19 onset with adjustment for age, sex, BMI &#x2265; 25, and COVID vaccination status prior to COVID-19 (brain fog: aRR 0.46, 95% CI 0.22-0.95; muscle pain: aRR 0.28, 95% CI 0.08-0.94). This work indicates that at least two long COVID symptoms - brain fog and muscle pain - at 90+ days from acute COVID-19 onset are specifically associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antar</LastName><ForeName>Annukka A R</ForeName><Initials>AAR</Initials><Identifier Source="ORCID">0000-0002-6775-1103</Identifier></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Tong</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Demko</LastName><ForeName>Zoe O</ForeName><Initials>ZO</Initials><Identifier Source="ORCID">0000-0003-2122-820X</Identifier></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Chen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0282-4532</Identifier></Author><Author ValidYN="Y"><LastName>Tornheim</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-1566-4622</Identifier></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Paul W</ForeName><Initials>PW</Initials><Identifier Source="ORCID">0000-0002-3817-5987</Identifier></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Manabe</LastName><ForeName>Yukari C</ForeName><Initials>YC</Initials><Identifier Source="ORCID">0000-0001-8619-5598</Identifier></Author><Author ValidYN="Y"><CollectiveName>OutSMART Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI135102</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Front Immunol. 2023 Apr 28;14:1147549. doi: 10.3389/fimmu.2023.1147549</RefSource><PMID Version="1">37187756</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>30</Day><Hour>3</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36711478</ArticleId><ArticleId IdType="pmc">PMC9882625</ArticleId><ArticleId IdType="doi">10.1101/2023.01.18.23284742</ArticleId><ArticleId IdType="pii">2023.01.18.23284742</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>